• Kissei and Rigel entered into an exclusive license and supply agreement to develop and commercialize fostamatinib disodium hexahydrate in all current and potential indications in Japan, China, Taiwan and the Republic of Korea.

  • Fostamatinib is commercially available in the U.S. under the brand name TAVALISSE® (fostamatinib disodium hexahydrate) and is the first and only SYK inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

  • Rigel received an upfront cash payment of $33 million, with the potential for an additional $147 million in development and commercial milestone payments, and will receive product transfer price payments in the mid to upper twenty percent range based on tiered net sales for the exclusive supply of product.

  • Kissei gains exclusive rights to fostamatinib in all current and potential indications in Japan and the other Asian countries.

*Please see the TAVALISSE full Prescribing Information at